Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Vaccines (gp100 and MART-1) in Metastatic Melanoma
NCT00019994Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 1999
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of gp100:44-59 in melanoma (3 arms), sponsored by National Cancer Institute. Primary endpoint: Clinical response to immunization. Started Oct 1999; status: completed.
02
Drugs
gp100:44-59
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00019994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019994.